MedTrace Logo

Prevalence, Awareness, Attitudes and Patterns of Stimulant Drug Use Among Students in Egyptian Universities

NCT06646822 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2025-10-02

No results posted yet for this study

Summary

Stimulants are dangerous drugs that are commonly abused by individuals looking to stay alert and focused, lose weight, stay awake, and get high. Although these drugs can be extremely harmful and even life-threatening, many of them can also be used to treat conditions like ADHD, narcolepsy, and in some cases, depression. There are many types of stimulant drugs, and it can be beneficial to know a little about each one, its purposes, and how harmful it can be when abused.

Illicit stimulants are usually schedule II, depending on whether or not they can be used to treat medical conditions. While some variations of stimulants are schedule I drugs, most are extremely addictive and dangerous schedule II substances. These drugs are often abused in a binge-crash pattern. According to the NIDA Teen, "In order to keep the 'high' going, people may take the drug repeatedly within a short period of time, at increasingly higher doses." This makes these drugs extremely addictive.

The aim of this survey to detect prevalence of non prescription stimulants in Egyptian students and increase their awareness of the harmful effects of these drugs.

Conditions

  • Study of Stimulants in Egypt

Interventions

OTHER

questionnaire

observational study

Sponsors & Collaborators

  • Asmaa Ahmed Hamed Mohie Eldin

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-10
Primary Completion
2025-04-30
Completion
2025-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06646822 on ClinicalTrials.gov